Browsing by Author "Humbert, Marc"

Now showing 1 - 3 of 3
  • Thumbnail Image
    Item
    Open Access
    Next-generation ARIA care pathways for rhinitis and asthma: a model for multimorbid chronic diseases
    (2019-09-09) Bousquet, J. J; Schünemann, Holger J; Togias, Alkis; Erhola, Marina; Hellings, Peter W; Zuberbier, Torsten; Agache, Ioana; Ansotegui, Ignacio J; Anto, Josep M; Bachert, Claus; Becker, Sven; Bedolla-Barajas, Martin; Bewick, Michael; Bosnic-Anticevich, Sinthia; Bosse, Isabelle; Boulet, Louis P; Bourrez, Jean M; Brusselle, Guy; Chavannes, Niels; Costa, Elisio; Cruz, Alvaro A; Czarlewski, Wienczyslawa; Fokkens, Wytske J; Fonseca, Joao A; Gaga, Mina; Haahtela, Tari; Illario, Maddalena; Klimek, Ludger; Kuna, Piotr; Kvedariene, Violeta; Le, L. T T; Larenas-Linnemann, Desiree; Laune, Daniel; Lourenço, Olga M; Menditto, Enrica; Mullol, Joaquin; Okamoto, Yashitaka; Papadopoulos, Nikos; Pham-Thi, Nhân; Picard, Robert; Pinnock, Hilary; Roche, Nicolas; Roller-Wirnsberger, Regina E; Rolland, Christine; Samolinski, Boleslaw; Sheikh, Aziz; Toppila-Salmi, Sanna; Tsiligianni, Ioanna; Valiulis, Arunas; Valovirta, Erkka; Vasankari, Tuula; Ventura, Maria-Teresa; Walker, Samantha; Williams, Sian; Akdis, Cezmi A; Annesi-Maesano, Isabella; Arnavielhe, Sylvie; Basagana, Xavier; Bateman, Eric; Bedbrook, Anna; Bennoor, K. S; Benveniste, Samuel; Bergmann, Karl C; Bialek, Slawomir; Billo, Nils; Bindslev-Jensen, Carsten; Bjermer, Leif; Blain, Hubert; Bonini, Mateo; Bonniaud, Philippe; Bouchard, Jacques; Briedis, Vitalis; Brightling, Christofer E; Brozek, Jan; Buhl, Roland; Buonaiuto, Roland; Canonica, Giorgo W; Cardona, Victoria; Carriazo, Ana M; Carr, Warner; Cartier, Christine; Casale, Thomas; Cecchi, Lorenzo; Cepeda Sarabia, Alfonso M; Chkhartishvili, Eka; Chu, Derek K; Cingi, Cemal; Colgan, Elaine; de Sousa, Jaime C; Courbis, Anne L; Custovic, Adnan; Cvetkosvki, Biljana; D’Amato, Gennaro; da Silva, Jane; Dantas, Carina; Dokic, Dejand; Dauvilliers, Yves; Dedeu, Antoni; De Feo, Giulia; Devillier, Philippe; Di Capua, Stefania; Dykewickz, Marc; Dubakiene, Ruta; Ebisawa, Motohiro; El-Gamal, Yaya; Eller, Esben; Emuzyte, Regina; Farrell, John; Fink-Wagner, Antjie; Fiocchi, Alessandro; Fontaine, Jean F; Gemicioğlu, Bilun; Schmid-Grendelmeir, Peter; Gamkrelidze, Amiran; Garcia-Aymerich, Judith; Gomez, Maximiliano; González Diaz, Sandra; Gotua, Maia; Guldemond, Nick A; Guzmán, Maria-Antonieta; Hajjam, Jawad; O’B Hourihane, John; Humbert, Marc; Iaccarino, Guido; Ierodiakonou, Despo; Illario, Maddalena; Ivancevich, Juan C; Joos, Guy; Jung, Ki-Suck; Jutel, Marek; Kaidashev, Igor; Kalayci, Omer; Kardas, Przemyslaw; Keil, Thomas; Khaitov, Mussa; Khaltaev, Nikolai; Kleine-Tebbe, Jorg; Kowalski, Marek L; Kritikos, Vicky; Kull, Inger; Leonardini, Lisa; Lieberman, Philip; Lipworth, Brian; Lodrup Carlsen, Karin C; Loureiro, Claudia C; Louis, Renaud; Mair, Alpana; Marien, Gert; Mahboub, Bassam; Malva, Joao; Manning, Patrick; De Manuel Keenoy, Esteban; Marshall, Gailen D; Masjedi, Mohamed R; Maspero, Jorge F; Mathieu-Dupas, Eve; Matricardi, Poalo M; Melén, Eric; Melo-Gomes, Elisabete; Meltzer, Eli O; Menditto, Enrica; Mercier, Jacques; Miculinic, Neven; Mihaltan, Florin; Milenkovic, Branislava; Moda, Giuliana; Mogica-Martinez, Maria-Dolores; Mohammad, Yousser; Montefort, Steve; Monti, Ricardo; Morais-Almeida, Mario; Mösges, Ralf; Münter, Lars; Muraro, Antonella; Murray, Ruth; Naclerio, Robert; Napoli, Luigi; Namazova-Baranova, Leila; Neffen, Hugo; Nekam, Kristoff; Neou, Angelo; Novellino, Enrico; Nyembue, Dieudonné; O’Hehir, Robin; Ohta, Ken; Okubo, Kimi; Onorato, Gabrielle; Ouedraogo, Solange; Pali-Schöll, Isabella; Palkonen, Susanna; Panzner, Peter; Park, Hae-Sim; Pépin, Jean-Louis; Pereira, Ana-Maria; Pfaar, Oliver; Paulino, Ema; Phillips, Jim; Picard, Robert; Plavec, Davor; Popov, Ted A; Portejoie, Fabienne; Price, David; Prokopakis, Emmanuel P; Pugin, Benoit; Raciborski, Filip; Rajabian-Söderlund, Rojin; Reitsma, Sietze; Rodo, Xavier; Romano, Antonino; Rosario, Nelson; Rottem, Menahenm; Ryan, Dermot; Salimäki, Johanna; Sanchez-Borges, Mario M; Sisul, Juan-Carlos; Solé, Dirceu; Somekh, David; Sooronbaev, Talant; Sova, Milan; Spranger, Otto; Stellato, Cristina; Stelmach, Rafael; Suppli Ulrik, Charlotte; Thibaudon, Michel; To, Teresa; Todo-Bom, Ana; Tomazic, Peter V; Valero, Antonio A; Valenta, Rudolph; Valentin-Rostan, Marylin; van der Kleij, Rianne; Vandenplas, Olivier; Vezzani, Giorgio; Viart, Frédéric; Viegi, Giovanni; Wallace, Dana; Wagenmann, Martin; Wang, De Y; Waserman, Susan; Wickman, Magnus; Williams, Dennis M; Wong, Gary; Wroczynski, Piotr; Yiallouros, Panayiotis K; Yorgancioglu, Arzu; Yusuf, Osman M; Zar, Heahter J; Zeng, Stéphane; Zernotti, Mario; Zhang, Luo; Zhong, Nan S; Zidarn, Mihaela
    Abstract Background In all societies, the burden and cost of allergic and chronic respiratory diseases are increasing rapidly. Most economies are struggling to deliver modern health care effectively. There is a need to support the transformation of the health care system into integrated care with organizational health literacy. Main body As an example for chronic disease care, MASK (Mobile Airways Sentinel NetworK), a new project of the ARIA (Allergic Rhinitis and its Impact on Asthma) initiative, and POLLAR (Impact of Air POLLution on Asthma and Rhinitis, EIT Health), in collaboration with professional and patient organizations in the field of allergy and airway diseases, are proposing real-life ICPs centred around the patient with rhinitis, and using mHealth to monitor environmental exposure. Three aspects of care pathways are being developed: (i) Patient participation, health literacy and self-care through technology-assisted “patient activation”, (ii) Implementation of care pathways by pharmacists and (iii) Next-generation guidelines assessing the recommendations of GRADE guidelines in rhinitis and asthma using real-world evidence (RWE) obtained through mobile technology. The EU and global political agendas are of great importance in supporting the digital transformation of health and care, and MASK has been recognized by DG Santé as a Good Practice in the field of digitally-enabled, integrated, person-centred care. Conclusion In 20 years, ARIA has considerably evolved from the first multimorbidity guideline in respiratory diseases to the digital transformation of health and care with a strong political involvement.
  • Thumbnail Image
    Item
    Open Access
    Overall asthma control achieved with budesonide/formoterol maintenance and reliever therapy for patients on different treatment steps
    (BioMed Central, 2011-12-01) Bateman, Eric D; Harrison, Tim W; Quirce, Santiago; Reddel, Helen K; Buhl, Roland; Humbert, Marc; Jenkins, Christine R; Peterson, Stefan; Östlund, Ollie; O'Byrne, Paul M; Sears, Malcolm R; Eriksson, Göran S
    Background: Adjusting medication for uncontrolled asthma involves selecting one of several options from the same or a higher treatment step outlined in asthma guidelines. We examined the relative benefit of introducing budesonide/formoterol (BUD/FORM) maintenance and reliever therapy (Symbicort SMART® Turbuhaler®) in patients previously prescribed treatments from Global Initiative for Asthma (GINA) Steps 2, 3 or 4. Methods: This is a post hoc analysis of the results of five large clinical trials (>12000 patients) comparing BUD/ FORM maintenance and reliever therapy with other treatments categorised by treatment step at study entry. Both current clinical asthma control during the last week of treatment and exacerbations during the study were examined. Results: At each GINA treatment step, the proportion of patients achieving target levels of current clinical control were similar or higher with BUD/FORM maintenance and reliever therapy compared with the same or a higher fixed maintenance dose of inhaled corticosteroid/long-acting b2-agonist (ICS/LABA) (plus short-acting b2-agonist [SABA] as reliever), and rates of exacerbations were lower at all treatment steps in BUD/FORM maintenance and reliever therapy versus same maintenance dose ICS/LABA (P < 0.01) and at treatment Step 4 versus higher maintenance dose ICS/LABA (P < 0.001). BUD/FORM maintenance and reliever therapy also achieved significantly higher rates of current clinical control and significantly lower exacerbation rates at most treatment steps compared with a higher maintenance dose ICS + SABA (Steps 2-4 for control and Steps 3 and 4 for exacerbations). With all treatments, the proportion of patients achieving current clinical control was lower with increasing treatment steps. Conclusions: BUD/FORM maintenance and reliever therapy may be a preferable option for patients on Steps 2 to 4 of asthma guidelines requiring a more effective treatment and, compared with other fixed dose alternatives, is most effective in the higher treatment steps.
  • Thumbnail Image
    Item
    Open Access
    Overall asthma control achieved with budesonide/formoterol maintenance and reliever therapy for patients on different treatment steps
    (BioMed Central Ltd, 2011) Bateman, Eric; Harrison, Tim; Quirce, Santiago; Reddel, Helen; Buhl, Roland; Humbert, Marc; Jenkins, Christine; Peterson, Stefan; Ostlund, Ollie; O'Byrne, Paul; Sears, Malcolm; Eriksson, Goran
    BACKGROUND: Adjusting medication for uncontrolled asthma involves selecting one of several options from the same or a higher treatment step outlined in asthma guidelines. We examined the relative benefit of introducing budesonide/formoterol (BUD/FORM) maintenance and reliever therapy (Symbicort SMART(R) Turbuhaler(R)) in patients previously prescribed treatments from Global Initiative for Asthma (GINA) Steps 2, 3 or 4. METHODS: This is a post hoc analysis of the results of five large clinical trials (>12000 patients) comparing BUD/FORM maintenance and reliever therapy with other treatments categorised by treatment step at study entry. Both current clinical asthma control during the last week of treatment and exacerbations during the study were examined. RESULTS: At each GINA treatment step, the proportion of patients achieving target levels of current clinical control were similar or higher with BUD/FORM maintenance and reliever therapy compared with the same or a higher fixed maintenance dose of inhaled corticosteroid/long-acting beta2-agonist (ICS/LABA) (plus short-acting beta2-agonist [SABA] as reliever), and rates of exacerbations were lower at all treatment steps in BUD/FORM maintenance and reliever therapy versus same maintenance dose ICS/LABA (P < 0.01) and at treatment Step 4 versus higher maintenance dose ICS/LABA (P < 0.001). BUD/FORM maintenance and reliever therapy also achieved significantly higher rates of current clinical control and significantly lower exacerbation rates at most treatment steps compared with a higher maintenance dose ICS + SABA (Steps 2-4 for control and Steps 3 and 4 for exacerbations). With all treatments, the proportion of patients achieving current clinical control was lower with increasing treatment steps. CONCLUSIONS: BUD/FORM maintenance and reliever therapy may be a preferable option for patients on Steps 2 to 4 of asthma guidelines requiring a more effective treatment and, compared with other fixed dose alternatives, is most effective in the higher treatment steps.